Halobetasol/lidocaine (Citius Pharmaceuticals)

卤倍他索/利多卡因(Citius Pharmaceuticals)

Report date: 2023/07/28 20:00:50

Base Information

Drug NameHalobetasol/lidocaine (Citius Pharmaceuticals)
Drug Alias NameCITI-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhospholipases A2 inhibitorsCytosolic phospholipase A2 agonistsGlucocorticoid receptor agonists +[4] 
TargetsPhospholipases A2Glucocorticoid receptorCytosolic phospholipase A2 +[4] 
Therapy Area/IndicationsHemorrhoids
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCitius Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCitius Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHemorrhoids
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A